$KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naΓ―ve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Healthcare
Sector
Biotechnology
Industry
Victor Perlroth
CEO
109
Employees
$40.63
Current Price
$1.23B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $1,197,488.49 | 30,000 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $1,197,488.49 | 30,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $1,197,488.49 | 30,000 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $1,197,488.49 | 30,000 | ||
See activity going back 12 months β create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | BORGESON JOHN A. Chief Financial Officer | Sale | 12,692 | $39.14 | $496,764.88 | View Details |
| Apr 2, 2026 | BORGESON JOHN A. Chief Financial Officer | Sale | 600 | $41.77 | $25,062.00 | View Details |
| Apr 2, 2026 | BORGESON JOHN A. Chief Financial Officer | Sale | 12,477 | $40.29 | $502,698.33 | View Details |
| Apr 2, 2026 | BORGESON JOHN A. Chief Financial Officer | Sale | 4,231 | $40.88 | $172,963.28 | View Details |
3 more transactions available β create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$1.02
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available β create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$MDGL β MADRIGAL PHARMACEUTICALS, INC.via BAKER BROS. ADVISORS LP$CELC β Celcuity Inc.via BAKER BROS. ADVISORS LP$IMCR β Immunocore Holdings plcvia BAKER BROS. ADVISORS LP$TRDA β Entrada Therapeutics, Inc.via BAKER BROS. ADVISORS LP$KYMR β Kymera Therapeutics, Inc.via BAKER BROS. ADVISORS LP